Is the iShares Global Healthcare ETF (IXJ) one of the best ASX sector ETFs?

Healthcare has obviously been one of the main talking points of 2020 so far. Is the iShares Global Healthcare ETF (ASX: IXJ) one of the best ASX sector ETFs?

Sector ETFs

Sector ETFs focus on one of the Global Industry Classification Standard (GICS) sectors.

There are 11 GICS sectors and many smaller industries and sub-industries within these sectors. Some of the sectors include financials, energy, information technology, and healthcare.

Every listed company is categorised into one of the sectors. Therefore, a sector ETF will invest only in companies in a certain category.

iShares Global Healthcare ETF

The iShares Global Healthcare ETF invests in healthcare companies around the world. Around 70% of the ETF is made up of US-based companies, but there is also exposure to Switzerland, Japan, the UK, Denmark, Germany, and others.

The healthcare sector has a number of tailwinds pushing it forward. Globally, we have a growing and ageing population that will start to require greater amounts of care. The sector is also experiencing rapid growth in the use of technology to handle administrative tasks and data analysis which makes the industry more efficient.

The IXJ ETF has a long track record and has delivered growth of 15.97% per year over the last 10 years (although this is not indicative of future performance).

Fees and risks

The IXJ ETF charges a management fee of 0.47% per year. In terms of risks, the most obvious risk is the lack of diversification. While IXJ holds companies across several sub-sectors, they are all within the healthcare sector and will typically demonstrate a high correlation to each other.

Sector ETFs may be more suitable as a ‘satellite’ holding rather than a core holding; a small portion of your overall portfolio which is allocated to high-conviction and high-growth ideas. You can learn more about the core and satellite approach by watching episode 46 of The Australian Finance Podcast:

Another risk is the price of the healthcare companies within the portfolio. Using the iShares S&P 500 ETF (ASX: IVV) as a comparison, IVV has a P/E ratio of 21.9 compared to 26 for IXJ. The healthcare ETF also has a higher price-to-book ratio.

This suggests that, in general, healthcare companies are priced more optimistically than the overall market which could limit future share price growth.

To read more about IXJ, check out our free report here.

[ls_content_block id=”695″ para=”paragraphs”]

 

Disclosure: At the time of publishing, Max owns units in the iShares S&P 500 ETF (ASX:IVV).

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report, and 24/7 access to the Rask community, for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Disclosure: At the time of publishing, Max owns units in the iShares S&P 500 ETF (ASX:IVV).

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.